Acquisition by Singh Vanila of 15000 shares of Virpax Pharmaceuticals subject to Rule 16b-3
| VRPX Stock | USD 0.31 0.01 3.13% |
Slightly above 61% of Virpax Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Virpax Pharmaceuticals suggests that many traders are alarmed. Virpax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Virpax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Virpax |
Filed transaction by Virpax Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Virpax Pharmaceuticals Fundamental Analysis
We analyze Virpax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Virpax Pharmaceuticals is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Virpax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Virpax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Virpax Pharmaceuticals Related Equities
| NTRB | Nutriband | 8.07 | ||||
| LGVN | Longeveron LLC | 3.90 | ||||
| PRAX | Praxis Precision | 2.95 | ||||
| REVB | Revelation Biosciences | 2.69 | ||||
| KPRX | Kiora Pharmaceuticals | 1.01 | ||||
| BDRX | Biodexa Pharmaceticals | 0.24 | ||||
| RNXT | RenovoRx | 0.74 | ||||
| KTTA | Pasithea Therapeutics | 1.59 | ||||
| PALI | Palisade Bio | 4.67 | ||||
| QNRX | Quoin Pharmaceuticals | 6.45 | ||||
| VRAX | Virax Biolabs | 11.98 |
Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.